The immunophilin ligand GPI-1046 does not have neuroregenerative effects in MPTP-treated monkeys

Exp Neurol. 2002 Dec;178(2):236-42. doi: 10.1006/exnr.2002.8023.

Abstract

Nonimmunosuppressant immunophilin ligands have been shown to have neurotrophic properties in rodent models of Parkinson's disease (PD), although little is known about the effects of these ligands in primates. The immunophilin ligand, GPI-1046, promotes the regeneration of dopamine (DA) cells in association with functional recovery in rodent models. We explored the regenerative effects of GPI-1046 in an MPTP primate model of PD. We used single photon emission computed tomography (SPECT) and the DA transporter tracer (DAT), [(123)I]beta-CIT, to evaluate DAT density and clinical recovery before and after treatment with GPI-1046 or vehicle. Subsequent histological studies were also performed. No effects of GPI-1046 were found on any of these measures. These findings show that GPI-1046 does not have regenerative effects in MPTP-treated primates and suggest that there may be species differences with respect to the trophic effects of GPI-1046 on nigrostriatal DA neurons.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Immunophilins / metabolism*
  • Immunophilins / pharmacology
  • Immunophilins / therapeutic use
  • Ligands
  • MPTP Poisoning / drug therapy*
  • MPTP Poisoning / metabolism
  • MPTP Poisoning / physiopathology
  • Macaca mulatta
  • Nerve Regeneration / drug effects*
  • Nerve Regeneration / physiology
  • Pyrrolidines / metabolism
  • Pyrrolidines / pharmacology*
  • Pyrrolidines / therapeutic use*

Substances

  • GPI 1046
  • Ligands
  • Pyrrolidines
  • Immunophilins